Skip to search formSkip to main contentSkip to account menu

elgodipine

Known as: 3,5-Pyridinedicarboxylic acid, 4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-, 2-(((4-fluorophenyl)methyl)methylamino)ethyl 1-methylethyl ester, (+-)-, isopropyl (2-(N-methyl-N-(4-fluorobenzyl)amine)ethyl-2,6-dimethyl-4-(2',3'-methylenedioxyphenyl)-1,5-dihydropyridine-3,5-dicarboxylate) 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
UNLABELLED OBJECTIVE, SUBJECTS AND METHODS: The 1,4-dihydropyridine elgodipine was given as continuous infusion at various rates… 
1996
1996
SummaryUsing an echo-Doppler method (Quantascope), the hemodynamic profile of the calcium channel antagonist elgodipine (64 μg/kg… 
1995
1995
SummaryElgodipine is a new second-generation dihydropyridine calcium antagonist. Its hemodynamic and antiischemic properties were… 
1994
1994
1 The haemodynamic profile of elgodipine (1–30 μg kg−1, i.v.), a new dihydropyridine calcium antagonist, has been compared… 
1994
1994
The effects of oral elgodipine, a new dihydropyridine calcium antagonist on ischaemia and left ventricular function were assessed… 
1994
1994
Summary— We studied the effects of six dihydropyridines on the specific binding of (+)‐[3H]‐isradipine to vascular (portal vein… 
1991
1991
The cardiovascular effects of the phenyldihydropyridine deriative elgodipine (0. 3, 1, 3, 10, and 30 γ/kg/min) were studied in… 
1990
1990
1 The central and regional cardiovascular responses to intravenous (0.3, 1.0, 3.0 and 10.0 μg kg−1 min−1) and intracoronary (0.3…